Morita D, Hirabayashi K, Katsuyama Y, Morokawa H, Motobayashi M, Kurata T, Shigemura T, Tanaka M, Inaba Y, Koike K, Nakazawa Y
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.
Transpl Infect Dis. 2016 Oct;18(5):773-776. doi: 10.1111/tid.12579. Epub 2016 Sep 7.
We describe successful treatment of 3 cases of human herpesvirus 6 (HHV-6) encephalitis/myelitis following cord blood transplantation (CBT). Ganciclovir (GCV) (10 mg/kg/day) reduced HHV-6 load to undetectable levels in cerebrospinal fluid (CSF). Early dose reduction in the presence of HHV-6 detectable in CSF resulted in an increased HHV-6 load. GCV was capably shifted to valganciclovir (VGCV) with an almost equivalent concentration. GCV/VGCV may be effective for HHV-6 encephalitis/myelitis after CBT, although HHV-6 load in CSF should be monitored.
我们描述了3例脐带血移植（CBT）后发生人疱疹病毒6型（HHV-6）脑炎/脊髓炎的成功治疗案例。更昔洛韦（GCV）（10mg/kg/天）可将脑脊液（CSF）中的HHV-6载量降至检测不到的水平。在脑脊液中可检测到HHV-6时提前减少剂量会导致HHV-6载量增加。GCV能够转换为浓度几乎相当的缬更昔洛韦（VGCV）。尽管应监测脑脊液中的HHV-6载量，但GCV/VGCV可能对CBT后的HHV-6脑炎/脊髓炎有效。
